-

CORRECTING and REPLACING Fulgent Genetics to Announce Second Quarter 2021 Financial Results on Monday, August 9, 2021

CORRECTION...by Fulgent Genetics, Inc.

TEMPLE CITY, Calif.--(BUSINESS WIRE)--In the headline and first paragraph, first sentence of release, the date should read: Monday, August 9, 2021 (instead of Thursday, August 5, 2021).

The updated release reads:

FULGENT GENETICS TO ANNOUNCE SECOND QUARTER 2021 FINANCIAL RESULTS ON MONDAY, AUGUST 9, 2021

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that it will release its second quarter 2021 financial results after the market closes on Monday, August 9, 2021. The company’s Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim, Chief Commercial Officer Brandon Perthuis, and Chief Medical Officer Dr. Larry Weiss will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer questions.

The call can be accessed through a live audio webcast in the Investors section of the company’s website, http://ir.fulgentgenetics.com, and through a live conference call by dialing (800) 437-2398 using the confirmation code 5019459. An audio replay will be available in the Investors section of the company’s website.

About Fulgent Genetics

Fulgent Genetics’ proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy and competitive turnaround times. Combining next generation sequencing (“NGS”) with its technology platform, the Company performs full-gene sequencing with deletion/duplication analysis in an array of panels that can be tailored to meet specific customer needs. A cornerstone of the Company’s business is its ability to provide expansive options and flexibility for all clients’ unique testing needs through a comprehensive technology offering including cloud computing, pipeline services, record management, web portal services, clinical workflow, sequencing as a service and automated lab services.

Contacts

Investor Relations Contacts:
The Blueshirt Group
Nicole Borsje, 415-217-2633
nicole@blueshirtgroup.com

Fulgent Genetics, Inc.

NASDAQ:FLGT

Release Versions
$Cashtags

Contacts

Investor Relations Contacts:
The Blueshirt Group
Nicole Borsje, 415-217-2633
nicole@blueshirtgroup.com

More News From Fulgent Genetics, Inc.

Fulgent to Participate in Upcoming Conferences

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that members of its management team are scheduled to present at the following upcoming investor conferences: UBS Global Healthcare Conference on Monday, November 10th at 5:00 PM Eastern Time Piper Sandler 37th Annual Healthcare Conference on Tuesday, December...

Fulgent Reports Third Quarter 2025 Financial Results

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its third quarter ended September 30, 2025. Third Quarter 2025 Results: Revenue of $84.1 million, growing 17% year-over-year GAAP loss of $6.6 million, or ($0.21) per share Non-GAAP income of $4.5 million, or $0.14 per share Adjusted EBI...

Fulgent Shares Preliminary Data from Poster Presentation at ESMO 2025 Conference

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced preliminary clinical data as of September 25, 2025, the preliminary data cutoff from its ongoing phase 2 clinical trial investigating FID-007 in combination with cetuximab in ≤ 2nd line treatment of patients diagnosed with recurrent or metastatic head and neck...
Back to Newsroom